| Trial ID # | NCT04516447 |
| Phase | I |
| Drug Class | Cell Cycle Inhibitors: WEE1 |
| Drug Name | Azenosertib |
| Alternate Drug Names | ZN-c3 |
| Drugs in Trial | Azenosertib, Carboplatin, Liposomal doxorubicin, Paclitaxel, Gemcitabine |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 115; median 2 prior therapies (1-4); 79.1% Pt-R, 20.9% Pt-Rf |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, PFS, evaluated per RECIST |
| Biomarkers | Exploratory: CCNE1 AMP |
| Efficacy | Aze+CarboPt: 36 evaluable: ORR: 35.7%; DoR: 11.4 months; DCR (4 months): 57.1%; PFS: 10.4 months |
| Clinically Significant Adverse Events | Aze+chemotherapy vs Aze: |
| Conclusion | Azenosertib (ZN-c3), combined with chemotherapy, is well-tolerated and demonstrates clinical activity in patients with Pt-R or Pt-Rf OC |
| Reference | Pasic et al. A phase 1b dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy (CT) in subjects with platinum-resistant or refractory ovarian, peritoneal, or fallopian tube cancer. Cancer Res (2022) 82 (12_Supplement): CT148 Pasic A et al. Poster Liu JF et al. Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). J Clin Oncol 41, 2023 (suppl 16; abstr 5513) Liu JF et al. Poster |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.